Embecta Corp. (EMBC)

Market Cap	1.57B
Revenue (ttm)	1.13B
Net Income (ttm)	223.60M
Shares Out	57.21M
EPS (ttm)	3.89
PE Ratio	7.03
Forward PE	n/a
Dividend	$0.30 (1.10%)
Ex-Dividend Date	Aug 25, 2022

Volume	568,493
Open	26.34
Previous Close	26.39
Day's Range	25.69 - 27.68
52-Week Range	22.30 - 49.00
Beta	n/a
Analysts	Sell
Price Target	27.03 (-1.21%)
Earnings Date	Feb 14, 2023

About EMBC

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1924
• Employees: 1,900
• Stock Exchange: NASDAQ
• Ticker Symbol: EMBC

Financial Performance

In 2022, Embecta's revenue was $1.13 billion, a decrease of -3.07% compared to the previous year's $1.17 billion. Earnings were $223.60 million, a decrease of -46.09%.

Analyst Forecast

According to 8 analysts, the average rating for EMBC stock is "Sell." The 12-month stock price forecast is $27.03, which is a decrease of -1.21% from the latest price.

Price Target

$27.03

(-1.21% downside)

Analyst Consensus: Sell